Research on the use of cannabis by persons with major depressive disorder and bipolar disorder clearly demonstrates that ...

Alcohol use disorder (AUD) is a major global public health issue, affecting more than 28 million adults in the United States ...

There is a connection between alcohol and anxiety the day after you drink for many reasons, even if you’ve not been diagnosed ...

For years, people taking GLP-1 type drugs (e.g., Ozempic, Wegovy) have noticed that the medicines didn’t just help them to ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

More than 60 percent of Vermont residents drink, a figure that’s nearly 10 percent higher than the U.S. average.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...